C-peptide vs Ziconotide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Ziconotide (ω-Conotoxin MVIIA (ziconotide)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Ziconotide |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Connecting peptide (C-peptide) | ω-Conotoxin MVIIA (ziconotide) |
| Molecular Weight | 3020.3 Da | 2639.1 Da |
| Half-Life | ~20-30 min | approximately 4.5 hours |
| Amino Acids | 31 | 25 |
| Typical Dose | no approved analgesic dose|research-only | 0.5-19.2 mcg/day |
| Route | IV|subQ | Intrathecal |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 500 |
| Research Status | Pre-clinical | Approved |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Ziconotide Benefits
- ✓strong non-opioid analgesia
- ✓effective for refractory neuropathic pain
- ✓opioid-sparing option
- ✓intrathecal delivery allows targeted action
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Ziconotide Dosing
start 0.5 mcg/day intrathecal|titrate by 0.5 mcg/day no more than 2 times weekly|max 19.2 mcg/day in labeling
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Ziconotide Side Effects
- ⚠dizziness
- ⚠confusion
- ⚠ataxia
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Ziconotide
Clinical studies and post-marketing data support ziconotide as an analgesic for severe chronic pain that does not respond to conventional therapy. Research focuses on balancing analgesic efficacy with neuropsychiatric tolerability and careful dose titration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.